Bristol-Myers Squibb Co., of New York, said the European Commission approved Daklinza (daclatasvir), a pan-genotypic NS5A replication complex inhibitor, for use in combination with other products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults.